Rhythm Pharmaceuticals (RYTM) Price & Analysis

Compare

543 Followers

RYTM Stock Chart & Stats

Day’s Range― - ―

52-Week Range$45.91 - $106.52

Previous CloseN/A

Volume91.33K

Average Volume (3M)560.05K

Market Cap

$6.92B

Enterprise Value$3.99B

Total Cash (Recent Filing)$291.03M

Total Debt (Recent Filing)$4.19M

Price to Earnings (P/E)―

Beta2.05

Next Earnings

Nov 11, 2025

EPS Estimate

-0.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.75

Shares Outstanding66,420,090

10 Day Avg. Volume547,041

30 Day Avg. Volume560,054

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue25.55

Enterprise Value/Gross Profit28.63

Enterprise Value/Ebitda-25.01

Forecast

1Y Price Target

$112.08

Price Target Upside7.18% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say

Financial PerformanceFinancial results were encouraging, with Imcivree sales for 2Q being $48.5M, above consensus estimates.

Market OpportunitySetmelanotide hits in the Phase 3 TRANSCEND trial for hypothalamic obesity, unlocking a multi billion-dollar opportunity and derisking the next-generation MC4R agonists.

Regulatory AdvancementsThe FDA accepted the sNDA filing for setmelanotide with Priority Review for conditions associated with acquired hypothalamic obesity.

Bears Say

Clinical ChallengesThe challenge will be demonstrating a clear signal against the noise of this complex condition, given the heterogeneity of Prader-Willi syndrome.

Operational CostsRYTM delivered a topline beat for 2Q25, offset by increased OpEx due to clinical trial costs.

Rhythm Pharmaceuticals News

Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide

Rhythm Pharmaceuticals (RYTM) announced that the FDA has accepted for filing the company’s supplemental new drug application for...

17d ago

RYTM

3 Best Stocks to Buy Now, 8/8/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

29d ago

WIX

Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results

Rhythm Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ulz from...

16d ago

RYTM

Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a Phase 3...

22d ago

RYTM

Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a study titled...

22d ago

RYTM

Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a Phase 3...

24d ago

RYTM

Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment

Rhythm Pharmaceuticals (($RYTM)) announced an update on their ongoing clinical study. Rhythm Pharmaceuticals is conducting a study titled...

24d ago

RYTM

Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals

Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on RYTM stock, giving a Buy rating today....

30d ago

RYTM

Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $100 from $80...

1M ago

RYTM

Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Rhythm Pharmaceuticals (($RYTM)) has held its Q2 earnings call. Read on for the main highlights of the call....

1M ago

RYTM

Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating

Analyst Derek Archila of Wells Fargo maintained a Buy rating on Rhythm Pharmaceuticals, retaining the price target of...

1M ago

RYTM

Optimistic Buy Rating for Rhythm Pharmaceuticals Driven by Strong Sales and Promising Growth Prospects

Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on RYTM stock, giving a Buy...

1M ago

RYTM

Rhythm Pharmaceuticals price target raised to $135 from $130 at Citizens JMP

Citizens JMP raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $135 from $130 and keeps an...

1M ago

RYTM

Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $109 from $100 and keeps an...

1M ago

RYTM

RYTM FAQ

What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?

Rhythm Pharmaceuticals Inc lowest stock price was $45.91 and its highest was $106.52 in the past 12 months.

What is Rhythm Pharmaceuticals Inc’s market cap?

Rhythm Pharmaceuticals Inc’s market cap is $6.92B.

When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?

Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Nov 11, 2025 which is in 66 days.

How were Rhythm Pharmaceuticals Inc’s earnings last quarter?

Rhythm Pharmaceuticals Inc released its earnings results on Aug 05, 2025. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.67 by -$0.08.

Is Rhythm Pharmaceuticals Inc overvalued?

According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rhythm Pharmaceuticals Inc pay dividends?

Rhythm Pharmaceuticals Inc does not currently pay dividends.

What is Rhythm Pharmaceuticals Inc’s EPS estimate?

Rhythm Pharmaceuticals Inc’s EPS estimate is -0.71.

How many shares outstanding does Rhythm Pharmaceuticals Inc have?

Rhythm Pharmaceuticals Inc has 66,420,090 shares outstanding.

What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?

Rhythm Pharmaceuticals Inc reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.67. Following the earnings report the stock price went down -1.851%.

Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in RYTM

Rhythm Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-1334.54%

Trailing 12-Months

Asset Growth

-2.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare genetic disorders of obesity. The company operates primarily in the biotechnology sector and is committed to addressing unmet medical needs in patients suffering from these conditions. Rhythm's core product, Imcivree (setmelanotide), is specifically designed to target the underlying biological mechanisms of obesity due to certain genetic causes, enhancing patient outcomes and quality of life.

Rhythm Pharmaceuticals (RYTM) Earnings & Revenues

Historic Earnings Reports

RYTM Company Deck

RYTM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong financial performance and significant progress in international market expansion and clinical trials, particularly for setmelanotide in acquired hypothalamic obesity. However, challenges remain in the Prader-Willi Syndrome trial and rising operating expenses.View all RYTM earnings summaries

RYTM Stock 12 Month Forecast

Average Price Target

$112.08

▲(7.18% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"$45","136":"$136","67.75":"$67.8","90.5":"$90.5","113.25":"$113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,67.75,90.5,113.25,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.3,91.8923076923077,95.48461538461538,99.07692307692308,102.66923076923077,106.26153846153846,109.85384615384615,113.44615384615385,117.03846153846153,120.63076923076923,124.22307692307692,127.81538461538462,131.40769230769232,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.3,90.12923076923077,91.95846153846153,93.78769230769231,95.61692307692307,97.44615384615385,99.27538461538461,101.10461538461539,102.93384615384615,104.76307692307692,106.59230769230768,108.42153846153846,110.25076923076924,{"y":112.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.3,88.81538461538462,89.33076923076923,89.84615384615384,90.36153846153846,90.87692307692308,91.3923076923077,91.9076923076923,92.42307692307692,92.93846153846154,93.45384615384616,93.96923076923076,94.48461538461538,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.77,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.01,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.43,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.91,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.3,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >